Organon &

Organon & Debt

The Debt of Organon & (OGN) as of Nov 11, 2026 is 8.68 B USD. In the previous year, Debt was 8.88 B USD — a change of -2.21% (lower).

Debt

8.68 BUSD

YoY

-2.21%

Last updated:

In 2025, Organon &'s total debt was 8.68 B USD, a -2.21% change from the 8.88 B USD total debt recorded in the previous year.

The Organon & Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2018
34.00 M USD
Jan 1, 2019
70.00 M USD
Jan 1, 2020
1.34 B USD
Jan 1, 2021
9.13 B USD
Jan 1, 2022
8.91 B USD
Jan 1, 2023
8.76 B USD
Jan 1, 2024
8.88 B USD
Jan 1, 2025
8.68 B USD
The Organon & Debt history
YEARDebtYoY
8.68 BUSD-2.21%
8.88 BUSD+1.37%
8.76 BUSD-1.72%
8.91 BUSD-2.42%
9.13 BUSD+582.15%
1.34 BUSD+1,812.86%
70.00 MUSD+105.88%
34.00 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Organon & Stock analysis

What does Organon & do? Organon & Co. generates revenue through prescription therapies and medical devices focused on women’s health, biosimilars, and established brands. Key products include contraception and fertility solutions like Nexplanon, Implanon NXT, NuvaRing, Follistim AQ, and Elonva, alongside biosimilars for immunology and oncology. Established brands cover cardiovascular, respiratory, dermatology, and non-opioid pain management segments. The company sells directly to drug wholesalers, retailers, hospitals, government agencies, and managed healthcare providers such as health maintenance organizations and pharmacy benefit managers. Organon’s portfolio targets healthcare institutions and providers, with products distributed through established pharmaceutical channels. The company’s biosimilars and women’s health brands drive sales in specialized medical markets, while established brands serve broader therapeutic areas. Revenue streams are derived from direct sales to healthcare systems and institutions that manage patient care across multiple therapeutic categories. The firm’s strategy centers on delivering innovative health solutions via a diversified product portfolio. Prescription therapies for women’s health, including contraceptive and fertility treatments, form a significant segment of sales. Biosimilars in immunology and oncology, alongside established brands in cardiovascular and respiratory care, contribute to recurring revenue from institutional buyers. Organon & is one of the most popular companies on Eulerpool.

Debt Details

Understanding Organon &'s Debt Structure

Organon &'s total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Organon &'s debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Organon &’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Organon &’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Organon & stock

Debt of Organon & is 8.68 B USD in 2025.

Debt of Organon & changed from 8.88 B USD to 8.68 B USD, representing a -2.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Organon & since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Organon & historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Organon &

All Key Metrics — Organon &